BVF Partners AGIO Position
Exited7-Fund ConvergenceBVF Partners exited their position in Agios Pharmaceuticals Inc. (AGIO) in Q1 2025, after holding the stock for 4 quarters.
The position was first reported in Q2 2024 and has been tracked across 4 quarterly 13F filings.
AGIO is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Tebapivat in 47 days (May 31, 2026), making the timing of BVF's position particularly relevant.
Short interest stands at 10.6% of float with 8.0 days to cover, indicating significant bearish positioning against the stock.
About Agios Pharmaceuticals Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
10.6%
8.0 days to cover
BVF Partners AGIO Position History
Frequently Asked Questions
Does BVF Partners own AGIO?
No. BVF Partners exited their position in Agios Pharmaceuticals Inc. (AGIO) in Q1 2025. They previously held the stock for 4 quarters.
How many hedge funds own AGIO?
7 specialist biotech hedge funds currently hold AGIO, including Commodore Capital, Rock Springs Capital, Deep Track Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did BVF Partners first buy AGIO?
BVF Partners's position in AGIO was first reported in Q2 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is BVF Partners's AGIO position increasing or decreasing?
BVF Partners completely exited their AGIO position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
AGIOCompany Page →
All fund holders, insider trades, catalysts, and cash runway
BVF PartnersPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →